Traditionally, bevacizumab’s impact was understood mainly in terms of its effect on the tumor’s blood supply through VEGFA inhibition, but this does not fully explain the lack of sensitivity observed in certain highly vascularized tumors among some patients. Here, VEGFA is linked to neoplasm.